Replies to post #3573 on Marker Therapeutics Inc (MRKR)

[goodJohnhunting]

Since Galena had a successful Phase 2 result which prompted a Phase 3 test, I have to believe that with better epitopes, TapImmune will also have a successful Phase 2 that will lead to Phase 3.

A more robust and genuine epitope, would theoretically result in a more pronounced unraveling of TAP augmentation, IMO.

Also, Merck's success with Keytruda will definitely put immunotherapy into the spotlight which only helps TapImmune find more investors. Didn't they talk about immunotherapy during that Cancer broadcast special on tv last night? I didn't see it but someone mentioned that.

I'm not a fan of PD-1 therapeutics. To randomly stimulate T-cell production, is not specialized, and has been done before. I'm all about focused, and targeted therapy, and thus my interest in Taplmmune.

PD-1 modulation is deficient in what Taplmmune's vaccine stimulates, "transporters associated with antigen processing", IMO.

All the best,
John